Grant, A. J.; Eksteen, B.; Miles, A.; Lalor, P. F.; Hübscber, S. G.; Briskin, M.; Adams, D. H.
April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA11
Academic Journal
Because the gut and liver share a blood supply and are exposed to gut derived antigens we hypothesised that T cells might undergo an enterohepatic recirculation. If so, this could explain the strong association between inflammatory bowel disease and primary sclerosing cholangitis (PSC). Authors have previously shown that Mucosal Addressin Cell Adhesion Molecule-1, which is usually restricted to gut endothelium, is also expressed by hepatic portal endothelium in PSC, and is capable of supporting a4b7 mediated lymphocyte adhesion. Here, authors demonstrate expression of the gut associated chemokine CCL25 on hepatic sinusoidal endothelium.


Related Articles

  • VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice. Soriano, Antonio; Salas, Antonio; Salas, Azucena; Sans, Miquel; Gironella, Meritxell; Elena, Monserrat; Anderson, Donald C.; Piqué, Josep M.; Panés, Julián // Laboratory Investigation (00236837);Oct2000, Vol. 80 Issue 10, p1541 

    Adhesion molecule immunoneutralization is envisioned as a promising therapy for inflammatory bowel disease, but the relative value of selective blockade of different adhesion molecules has not been established. The aims of this study were to measure expression and functional relevance of...

  • Novel Treatment Options for Inflammatory Bowel Disease: Targeting α4 Integrin. Lanzarotto, Francesco; Carpani, Marta; Chaudhary, Rakesh; Ghosh, Subrata // Drugs;2006, Vol. 66 Issue 9, p1179 

    The aetiology of inflammatory bowel disease (IBD) is complex and many aspects still remain unclear. However, significant progress has been made in understanding the pathogenesis of chronic inflammation in the intestine, and new insights have been gained recently. A better understanding of the...

  • CHARACTERISATION OF MUCOSAL ADDRESSIN CELL ADHESION MOLECULE (MADCAM-1) IN INFLAMMATORY BOWEL DISEASE. Ala, A.; Stubbs, M.; Coward, S.; Brown, D.; Hodgson, H.J. // Gut;Apr2003 Supplement 1, Vol. 52, pA39 

    Introduction: MAdCAM-1 is an endothelial cell adhesion glycoprorein that regulates α4β7 lymphocyte trafficking. It is upregulated in active inflammatory bowel disease (IBD). No satisfactory in vitro models of MAdCAM-1 expression have been described. In vitro, brain endothelium (bEnd3) is...

  • Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Sandborn, William J.; Yednock, Ted A. // American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2372 

    Crohn''s disease involves persistent recruitment of leukocytes into gut tissue, coupled with dysregulated activation of specific immune cell function. Adhesion molecules expressed by circulating leukocytes, such as α4 integrin, mediate their attachment to vascular endothelial cells lining...

  • Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Thomas, Saskia; Baumgart, Daniel // Inflammopharmacology;Feb2012, Vol. 20 Issue 1, p1 

    Crohn's disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to blocking tumor necrosis factor alpha. However, some patients are primary non-responders, experience a loss of response, intolerance or side effects defining the urgent...

  • Perception of eye contact in video teleconsultation. Tam, Tony; Cafazzo, Joseph A.; Seto, Emily; Salenieks, Mary Ellen; Rossos, Peter G. // Journal of Telemedicine & Telecare;Jan2007, Vol. 13 Issue 1, p35 

    During patient consultations by videoconferencing, clinicians often sit as close as 1 m from the videoconferencing units, creating a significant eye gaze angle (i.e. the angle between the eye and the camera, and the eye and the centre of the display). Eye gaze angle may adversely affect the...

  • New therapeutic approach in inflammatory bowel disease. PAPA, A.; MOCCI, G.; SCALDAFERRI, F.; BONIZZI, M.; FELICE, C.; ANDRISANI, G.; GASBARRINI, A. // European Review for Medical & Pharmacological Sciences;Jan2009 Supplement, Vol. 13 Issue S-1, p33 

    In the last decade, biologic agents, in particular infliximab and adalimumab, have deeply changed the therapeutic armamentarium of inflammatory bowel disease (IBD). However, these drugs have a number of contraindications and side-effects that physicians should know so to avoid and eventually...

  • Utilization of Health Care Resources by Individuals with Inflammatory Bowel Disease in the United States: A Profile of Time Since Diagnosis. Longobardi, Teresa; Jacobs, Phillip; Bernstein, Charles N. // American Journal of Gastroenterology;Apr2004, Vol. 99 Issue 4, p650 

    BACKGROUND: There are no cost studies of inflammatory bowel disease (IBD) that describe its impact on resource utilization or treatment costs over long periods of time. Our aim was to determine if there are observable trends in health-care resource utilization by adults with IBD depending on...

  • Acute Idiopathic Pancreatitis Complicating Active Crohn's Disease: Favorable Response to Infliximab Treatment. Triantafillidis, John K.; Cheracakis, Petros; Hereti, Irini A.; Argyros, Nikolaos; Karra, Evangelia // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3334 

    Reports on the case of a male patient with Crohn's disease involving concurrently the small and large bowel, which developed idiopathic acute pancreatitis during a severe flare-up of his underlying inflammatory bowel disease. Medical history of the patient; Response of the patient to infliximab...


Read the Article


Sign out of this library

Other Topics